Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Breast Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-10-21

Study Completion Date

2039-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an observational study for patients with breast cancer that will be treated with doxorubicin (Adriamycin) and/or trastuzumab (Herceptin). The study will help the investigators learn more about how these medications affect the heart and how those effects relate to patients' medical history and social determinants of health (such as race, gender identity, education, occupation, access to health services and economic resources). Patients on this study will have echocardiograms, blood draws, and answer questions about their symptoms and activity level. Patients will be followed on this study for up to 15 years.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery

NCT00436566

Breast Cancer Cardiac Toxicity

COMPLETED PHASE2

Early Detection and Prediction of Chemotherapy Induced Cardiac Toxicity in Breast Cancer Patients

NCT00806507

Breast Cancer

COMPLETED

Investigating the Long-term Cardiac Sequelae of Trastuzumab Therapy

NCT05019365

Breast Cancer HER2-positive Breast Cancer Cardiotoxicity

UNKNOWN

Phase II Trial to Compare the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy for HER2-positive Breast Cancer (Study P05048)

NCT00550771

Breast Neoplasm

COMPLETED PHASE2

Cardiac Toxicity in Medical Treatment of Breast Cancer

NCT02440620

Heart Failure Breast Cancer

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators propose a prospective longitudinal cohort of breast cancer patients treated with anthracyclines and/or trastuzumab to determine the associations between social determinants of health (SDOH) and cardiotoxicity risk and to determine whether associations between SDOH and cardiotoxicity risk differ according to race. Patients will be followed with serial echo, blood draw, and surveys every 3 months for the first year, then annually for two years. After 3 years following start of cancer therapy, patients will have study visits every other year for up to 15 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer Cardiotoxicity Drug-Related Side Effects and Adverse Reactions Cardiovascular Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

* Women older than 18 years of age
* Breast cancer with treatment plan that includes doxorubicin and/or trastuzumab
* Ability to provide written informed consent